C Baues1,2, R Semrau3,4, U S Gaipl5, P J Bröckelmann4,6, J Rosenbrock3, A Engert4,6, S Marnitz3,4. 1. Medical Faculty, Department of Radiooncology, University of Cologne, Cologne, Germany. christian.baues@uk-koeln.de. 2. German Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany. christian.baues@uk-koeln.de. 3. Medical Faculty, Department of Radiooncology, University of Cologne, Cologne, Germany. 4. German Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany. 5. Department of Radiooncology, University hospital Erlangen, Erlangen, Germany. 6. Medical Faculty, Department of Internal Medicine I, University of Cologne, Cologne, Germany.
Abstract
BACKGROUND: Patients with classical Hodgkin's lymphoma (cHL) have a good prognosis even in advanced stages. However, combined chemo- and radiotherapy, as the standard of care, is also associated with treatment-related toxicities such as organ damage, secondary neoplasias, infertility, or fatigue and long-term fatigue. Many patients suffer from this burden although their cHL was cured. Therefore, the efficacy of immune checkpoint inhibitors like anti-PD1/PD-L1 antibodies in the treatment of solid cancers and also in HL offers new options. A remarkable and durable response rate with a favorable toxicity profile was observed in heavily pretreated cHL patients. METHODS: Planning to perform prospective randomized clinical trials in the content of radio-immune treatment in patients with Hodgkin's lymphoma (HL), we transferred the results of preliminary clinical studies and basic research in clinical relevant study concepts. RESULTS: Based on these promising early phase trial data, the German Hodgkin Study Group (GHSG) will investigate innovative treatment regimens in upcoming phase II trials. CONCLUSION: The therapeutic efficacy and potential synergies of anti-PD1 antibodies in combination with chemo- or radiotherapy will be investigated in various settings of HL.
BACKGROUND:Patients with classical Hodgkin's lymphoma (cHL) have a good prognosis even in advanced stages. However, combined chemo- and radiotherapy, as the standard of care, is also associated with treatment-related toxicities such as organ damage, secondary neoplasias, infertility, or fatigue and long-term fatigue. Many patients suffer from this burden although their cHL was cured. Therefore, the efficacy of immune checkpoint inhibitors like anti-PD1/PD-L1 antibodies in the treatment of solid cancers and also in HL offers new options. A remarkable and durable response rate with a favorable toxicity profile was observed in heavily pretreated cHL patients. METHODS: Planning to perform prospective randomized clinical trials in the content of radio-immune treatment in patients with Hodgkin's lymphoma (HL), we transferred the results of preliminary clinical studies and basic research in clinical relevant study concepts. RESULTS: Based on these promising early phase trial data, the German Hodgkin Study Group (GHSG) will investigate innovative treatment regimens in upcoming phase II trials. CONCLUSION: The therapeutic efficacy and potential synergies of anti-PD1 antibodies in combination with chemo- or radiotherapy will be investigated in various settings of HL.
Entities:
Keywords:
Abscopal effect; Immune modulation; Organs at risk; Programmed cell death protein 1; Radio-immune therapy
Authors: J A Yared; N Hardy; Z Singh; S Hajj; A Z Badros; M Kocoglu; S Yanovich; E A Sausville; C Ujjani; K Ruehle; C Goecke; M Landau; A P Rapoport Journal: Bone Marrow Transplant Date: 2016-02-01 Impact factor: 5.483
Authors: Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp Journal: Blood Date: 2010-07-13 Impact factor: 22.113
Authors: John M M Raemaekers; Marc P E André; Massimo Federico; Theodore Girinsky; Reman Oumedaly; Ercole Brusamolino; Pauline Brice; Christophe Fermé; Richard van der Maazen; Manuel Gotti; Reda Bouabdallah; Catherine J Sebban; Yolande Lievens; Allessandro Re; Aspasia Stamatoullas; Frank Morschhauser; Pieternella J Lugtenburg; Elisabetta Abruzzese; Pierre Olivier; Rene-Olivier Casasnovas; Gustaaf van Imhoff; Tiana Raveloarivahy; Monica Bellei; Thierry van der Borght; Stephane Bardet; Annibale Versari; Martin Hutchings; Michel Meignan; Catherine Fortpied Journal: J Clin Oncol Date: 2014-03-17 Impact factor: 44.544
Authors: J Kriz; C Baues; R Engenhart-Cabillic; U Haverkamp; K Herfarth; P Lukas; H Schmidberger; S Marnitz-Schulze; M Fuchs; A Engert; H T Eich Journal: Strahlenther Onkol Date: 2016-09-27 Impact factor: 3.621
Authors: J Kriz; C Baues; R Engenhart-Cabillic; U Haverkamp; K Herfart; P Lukas; A Plütschow; H Schmidberger; S Staar; M Fuchs; A Engert; H T Eich Journal: Strahlenther Onkol Date: 2016-09-05 Impact factor: 3.621
Authors: Andrew B Sharabi; Christopher J Nirschl; Christina M Kochel; Thomas R Nirschl; Brian J Francica; Esteban Velarde; Theodore L Deweese; Charles G Drake Journal: Cancer Immunol Res Date: 2014-12-19 Impact factor: 11.151
Authors: Karolin Behringer; Helen Goergen; Felicitas Hitz; Josée M Zijlstra; Richard Greil; Jana Markova; Stephanie Sasse; Michael Fuchs; Max S Topp; Martin Soekler; Stephan Mathas; Julia Meissner; Martin Wilhelm; Peter Koch; Hans-Walter Lindemann; Enrico Schalk; Robert Semrau; Jan Kriz; Tom Vieler; Martin Bentz; Elisabeth Lange; Rolf Mahlberg; Andre Hassler; Martin Vogelhuber; Dennis Hahn; Jörg Mezger; Stefan W Krause; Nicole Skoetz; Boris Böll; Bastian von Tresckow; Volker Diehl; Michael Hallek; Peter Borchmann; Harald Stein; Hans Eich; Andreas Engert Journal: Lancet Date: 2014-12-22 Impact factor: 79.321
Authors: Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand Journal: N Engl J Med Date: 2014-12-06 Impact factor: 91.245
Authors: Qian Qin; Xinyu Nan; Tara Miller; Ronald Fisher; Bin Teh; Shruti Pandita; Andrew M Farach; Sai Ravi Pingali; Raj K Pandita; E Brian Butler; Tej K Pandita; Swaminathan P Iyer Journal: Radiat Res Date: 2018-06-27 Impact factor: 2.841
Authors: Markus Hecht; Thomas Harrer; Verena Körber; Eric O Sarpong; Fabian Moser; Nora Fiebig; Manuela Schwegler; Michael Stürzl; Rainer Fietkau; Luitpold V Distel Journal: Oncol Lett Date: 2017-12-05 Impact factor: 2.967
Authors: Benjamin Frey; Michael Rückert; Julia Weber; Xaver Mayr; Anja Derer; Michael Lotter; Christoph Bert; Franz Rödel; Rainer Fietkau; Udo S Gaipl Journal: Front Immunol Date: 2017-03-08 Impact factor: 7.561